Patents by Inventor Kerstin GUDE

Kerstin GUDE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Very low-dosed solid oral dosage forms for HRT
    Patent number: 9592245
    Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: March 14, 2017
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
  • VERY LOW-DOSED SOLID ORAL DOSAGE FORMS FOR HRT
    Publication number: 20150094287
    Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventors: Stephan MLETZKO, Rolf SCHÜRMANN, Kerstin GUDE
  • Very low-dosed solid oral dosage forms for HRT
    Patent number: 8906890
    Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: December 9, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Stephan Mletzko, Rolf Schurmann, Kerstin Gude
  • LOW-DOSED SOLID ORAL DOSAGE FORMS FOR HRT
    Publication number: 20130140210
    Abstract: The present invention relates to a low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.5 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the low E2 and DRSP doses it has surprisingly been found that a very high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
    Type: Application
    Filed: April 12, 2011
    Publication date: June 6, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
  • LOW-DOSED SOLID ORAL DOSAGE FORMS FOR HRT
    Publication number: 20130137664
    Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
    Type: Application
    Filed: April 12, 2011
    Publication date: May 30, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
  • VERY LOW-DOSED SOLID ORAL DOSAGE FORMS FOR HRT
    Publication number: 20110275601
    Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
    Type: Application
    Filed: April 15, 2011
    Publication date: November 10, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Stephan MLETZKO, Rolf SCHURMANN, Kerstin GUDE